Clovis abandons solo Rubraca's phase 2 test in bladder cancer by Tracy Staton Monday, April 15, 2019 Clovis Oncology's PARP inhibitor Rubraca didn't spur enough response to warrant continuing a phase 2 bladder cancer study.
Clovis' Rubraca puts up positive phase 2 pancreatic cancer data by Carly Helfand Tuesday, April 2, 2019 Lynparza earlier this year scored a phase 3 win in pancreatic cancer. Now, another PARP drug has shown some early success in the disease, too.
Clovis CEO to potential bidders: Step right up by Arlene Weintraub Friday, January 11, 2019 Clovis CEO Patrick Mahaffy is making it clear he’s ready to deal—and doing what he can to make the PARP player a top M&A target.
Clovis should put itself up for sale, activist says: report by Arlene Weintraub Tuesday, December 18, 2018 One of Clovis's largest investors reportedly wants the company to raise its hand for a buyout as it struggles to stand out in the PARP market.
Tesaro's deal process bodes well for Clovis: analyst by Carly Helfand Wednesday, December 19, 2018 PARP drugmaker Tesaro may have had a tough time finding a buyer. But that doesn’t mean rival Clovis won’t be able to land its own, one analyst says.
A replay of how Tesaro got its $5.1B GSK buyout by Angus Liu Monday, December 17, 2018 From nearly $190 per share when it first explored a sale to a $75 price that still upset GSK's investors, Tesaro walked a brambled path to the buyout.
Will Clovis be the next PARP maker to get swallowed up? by Arlene Weintraub Friday, December 7, 2018 Clovis is facing several challenges that have biopharma experts speculating it will be snapped up by an asset-hungry Big Pharma player.
Half of doctors are still wary of PARPs: executive by Carly Helfand Wednesday, October 24, 2018 Despite a field that features four entrants and a wealth of data supporting their use, some doctors still aren't on board with PARP inhibitors.
Clovis bolsters Rubraca's prostate cancer bid with response data by Carly Helfand Friday, October 19, 2018 Earlier this month, Clovis' Rubraca won the FDA’s breakthrough tag in prostate cancer. Now, Clovis has unveiled the data that got it the distinction.
